



EY Entrepreneur
of the year-2013



FROST & SULLIVAN
2013
BEST PRACTICES
AWARD



Business today/YES bank
Excellence Awards-2013



Date: 21st January, 2022

To BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
Security Code: 540596	Symbol: ERIS

SUBJECT: UPDATE ON INTIMATION DATED 29TH JULY, 2021

Dear Sir/Madam,

We invite your attention to the intimation titled “**INTIMATION IN TERMS OF REGULATION 30 READ WITH SCHEDULE III PART A (1)**” dated July 29th, 2021.

It is desired to update the members through the exchanges that pursuant to a review carried out in this regard by the company, it has emerged that the optimum source of funding for financing the greenfield project for the setting up of a formulations manufacturing facility at Gujarat (“Project”) would be a judicious mix of internal accruals and low cost borrowings as may be decided from time to time to improve project IRR. The Company shall accordingly avail such mix.

Thanking You,
For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary and Compliance Officer

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867